MetLife Investment Management’s Aerie Pharmaceuticals AERI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q4 | – | Sell |
-24,261
| Closed | -$367K | – | 2865 |
|
|
2022
Q3 | $367K | Buy |
24,261
+4,591
| +23% | +$53.4K | ﹤0.01% | 1861 |
|
|
2022
Q2 | $148K | Sell |
19,670
-4,596
| -19% | -$32.4K | ﹤0.01% | 2505 |
|
|
2022
Q1 | $221K | Buy |
24,266
+9,001
| +59% | +$69.4K | ﹤0.01% | 2295 |
|
|
2021
Q4 | $107K | Hold |
15,265
| – | – | ﹤0.01% | 2381 |
|
|
2021
Q3 | $174K | Hold |
15,265
| – | – | ﹤0.01% | 2179 |
|
|
2021
Q2 | $244K | Hold |
15,265
| – | – | ﹤0.01% | 2029 |
|
|
2021
Q1 | $273K | Sell |
15,265
-1,173
| -7% | -$20.3K | ﹤0.01% | 1874 |
|
|
2020
Q4 | $222K | Sell |
16,438
-3,002
| -15% | -$36.3K | ﹤0.01% | 1923 |
|
|
2020
Q3 | $229K | Hold |
19,440
| – | – | ﹤0.01% | 1788 |
|
|
2020
Q2 | $287K | Hold |
19,440
| – | – | ﹤0.01% | 1673 |
|
|
2020
Q1 | $262K | Hold |
19,440
| – | – | ﹤0.01% | 1549 |
|
|
2019
Q4 | $470K | Hold |
19,440
| – | – | ﹤0.01% | 1498 |
|
|
2019
Q3 | $374K | Hold |
19,440
| – | – | ﹤0.01% | 1570 |
|
|
2019
Q2 | $574K | Buy |
19,440
+3,048
| +19% | +$117K | 0.01% | 1393 |
|
|
2019
Q1 | $779K | Hold |
16,392
| – | – | 0.01% | 1196 |
|
|
2018
Q4 | $592K | Hold |
16,392
| – | – | 0.01% | 1260 |
|
|
2018
Q3 | $1.01M | Hold |
16,392
| – | – | 0.01% | 1115 |
|
|
2018
Q2 | $1.11M | Buy |
16,392
+1,066
| +7% | +$59.6K | 0.01% | 982 |
|
|
2018
Q1 | $831K | Hold |
15,326
| – | – | 0.01% | 1092 |
|
|
2017
Q4 | $916K | Buy |
+15,326
| New | +$929K | 0.01% | 1062 |
|
MetLife Investment Management's AERI Position: Q4 2022 in Review
MetLife Investment Management sold out of Aerie Pharmaceuticals (AERI) in Q4 2022, closing a stake of 24,261 shares — an estimated $367K sold.
MetLife Investment Management first reported a position in AERI in Q4 2017 and held it in 20 quarters. The position peaked at $1.11M in Q2 2018. 0 funds tracked by Wall St. Rank hold AERI as of Q4 2022.
- MetLife Investment Management reported no remaining Aerie Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
- MetLife Investment Management sold 24,261 Aerie Pharmaceuticals shares in Q4 2022, an estimated $367K.
- MetLife Investment Management first reported a position in Aerie Pharmaceuticals in Q4 2017 and held it in 20 quarters.
- MetLife Investment Management's Aerie Pharmaceuticals position peaked at $1.11M in Q2 2018.
- 0 funds tracked by Wall St. Rank held Aerie Pharmaceuticals as of Q4 2022.
Based on MetLife Investment Management's 13F filing for Q4 2022, filed 15 Feb 2023.